Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19 : Evaluation of Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of covid19
The associated use of Ivermectin, aspirin, dexamethasone, and enoxaparin (in different combinations and doses) will reduce the impact of COVID infection 19, the need of admission to the intensive care unit, and mortality..
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
ClinicalTrials.gov - (2020) vom: 19. Okt. Zur Gesamtaufnahme - year:2020 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
610 |
|---|
| Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: June 11, 2020, Last downloaded: ClinicalTrials.gov processed this data on June 14, 2021, Last updated: June 15, 2021 |
|---|
| fisyears: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
CTG003420612 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG003420612 | ||
| 003 | DE-627 | ||
| 005 | 20230425191041.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210408s2020 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG003420612 | ||
| 035 | |a (UBBS_Klinische_Studien)NCT04425863 | ||
| 035 | |a (UBBS_Klinische_Studien)IDEA | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19 |b Evaluation of Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of covid19 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: June 11, 2020, Last downloaded: ClinicalTrials.gov processed this data on June 14, 2021, Last updated: June 15, 2021 | ||
| 520 | |a The associated use of Ivermectin, aspirin, dexamethasone, and enoxaparin (in different combinations and doses) will reduce the impact of COVID infection 19, the need of admission to the intensive care unit, and mortality. | ||
| 650 | 2 | |a Severe Acute Respiratory Syndrome | |
| 650 | 2 | |a Pneumonia | |
| 650 | 4 | |a Medical Condition: Severe Acute Respiratory Syndrome, Ventilation Pneumonitis | |
| 650 | 4 | |a Study Type: Observational | |
| 650 | 4 | |a Recruitment Status: Completed | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2020) vom: 19. Okt. |
| 773 | 1 | 8 | |g year:2020 |g day:19 |g month:10 |
| 856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT04425863 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2020 |b 19 |c 10 | ||